

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox. ✓**



Atty Doc. No. HME/7477.014

p #2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION EXAMINING OPERATIONS

In re the Application of
Ronald Wetzel, et al.

:
:

Group Art Unit: 1645

Serial No. 10/082,673

:

Examiner:

Filed: February 22, 2002

:

Date: April 30, 2002

RECEIVED

MAY 08 2002

TECH CENTER 1600/2900

For a Patent for
POLYGLUTAMINE REPEAT SEQUENCES

**INFORMATION DISCLOSURE STATEMENT
IN ACCORDANCE WITH 37 CFR §1.98**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Applicant submits herewith copies of patents and publications of which he is aware and which he desires to have considered by the Patent Office in accordance with 37 CFR §1.97. In accordance with 37 CFR §1.97(b)(3), this Information Disclosure Statement is being submitted before the mailing date of a first Office Action on the merits of the above-identified application.

In accordance with 37 CFR §1.97(h), the filing of this Information Disclosure Statement will not be regarded as an admission that any patent or publication or combination of patents referred to herein is, or is considered to be, material to patentability under 37 CFR §1.56(b) unless specifically designated as such.

A list of the patents and publications enclosed herewith is set forth on the attached 3 pages of Information Disclosure Statement by Applicant.

The person making this statement is the attorney who signs below on the basis of the information supplied by the inventor and the information in his file.

Respectfully submitted,



Howard M. Eisenberg
Reg. No. 36,789
1600 ODS Tower
601 S.W. Second Avenue
Portland, OR 97204-3157
Attorney for Applicant
Tel: (503) 227-5631

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on April 30, 2002.

Dated: _____

4/30/2002



Howard M. Eisenberg

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Application Number	10/082,673
Filing Date	February 22, 2002
First Named Inventor	Ronald Wetzel
Group Art Unit	1645
Examiner Name	

Sheet	1	of	4
-------	---	----	---

Attorney's Docket No.	HME/7477.014
-----------------------	--------------

TECH CENTER 1600/2900

MAY 08 2002

RECEIVED

U.S. Patent Documents

Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, columns, lines where passages or relevant figures appear
		Number Code	Kind			
	AA					
	AB					
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					
	AL					
	AM					
	AN					
	AO					
	AP					
	AQ					

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

RECEIVED

MAY 08 2002

TECH CENTER 1600/2909



Sheet 2 of 4	Inventor: Wetzel et al
--------------	------------------------


FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No. ¹	FOREIGN PATENT DOCUMENTS			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YY	Pages, columns, lines where passages or relevant figures appear
		Office code	Number	Kind ²			
	B A						
	B B						
	B C						
	B D						
	B E						
	B F						
	B G						
	B H						
	B I						
	B J						

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language translation is attached.

RECEIVED

MAY 08 2002

TECH CENTER 1600/2900²

Sheet 3	4	Inventor:	Wetzel et al
---------	---	-----------	--------------

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite, No.	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and or country where published
	C A	PERUTZ, MF, et al., "Glutamine repeats as polar zippers: Their possible role in inherited neurodegenerative diseases", Proc. Nat. Acad. Sci., 91:5355-5358 (1994)
	C B	WETZEL, R., "Protein Aggregation <i>in vivo</i> ", in Stability of Protein Pharmaceuticals: Part B: In Vivo Pathways of Degradation and Strategies for Protein Stabilization, ed. Ahern, TJ and Manning, MC, Plenum Press, New York, pages 43-88 (1992)
	C C	WETZEL, R., "Mutations and off-pathway aggregation of proteins", Trends in Biotechnology, 12(5):193-198 (1994)
	C D	WETZEL, R., "For protein misassembly, it's the 'I' decade", Cell, 86:699-702 (1996)
	C E	SCHERZINGER, et al., "Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: Implications for Huntington's disease pathology", Proc. Natl. Acad. Sci., 96:4604-4609 (1999)
	C F	SCHERZINGER, et al., "Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates <i>in vitro</i> and <i>in vivo</i> ", Cell, 90:549-558 (1997)
	C G	HEISER, et al., "Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy", PNAS, 97(12):6739-6744 (2000)
	C H	SHARMA et al., "Peptide models for inherited neurologic disorders: conformation and aggregation properties of long polyglutamine peptides with and without interruptions", FEBS Letters, 456:181-185 (1999)
	C I	ESTER et al., "A β deposition inhibitor screen using synthetic amyloid", Nature Biotechnology, 15:258-263 (1997)
	C J	ESLER et al., "Deposition of soluble amyloid- β onto amyloid templates: With application for the identification of amyloid fibril extension inhibitors", Methods in Enzymology, 309:350-374 (1999)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language translation is attached.

RECEIVED

MAY 08 2002

TECH CENTER 1600/2980



Sheet	4	of		Inventor:	Wetzel et al
-------	---	----	--	-----------	--------------

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS			T ²
Examiner Initials	Cite No.	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and or country where published	
	C K	BOHRMANN, et al., "Endogenous proteins controlling amyloid β -peptide polymerization", J. Biological Chemistry, 274(23):15990-15995 (1999)	
	C L	JAO, et al., "Trifluoroacetic acid pretreatment reproducibly disaggregates the amyloid β -peptide", Amyloid: Int. J. Exp. Clin. Invest., 4:240-252 (1997)	
	C M	ZAGORSKI, et al., "Methodological and chemical factors affecting amyloid β peptide amyloidogenicity", Methods in Enzymology, 309:189-204 (1999)	
	C N	EVANS, et al., "Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implications for the pathogenesis and treatment of Alzheimer disease", Proc. Natl. Acad. Sci., 92:763-767 (1995)	
	C O	LeVINE, H, and SCHOLTEN, JD, "Screening for Pharmacologic inhibitors of amyloid fibril formation", Methods in Enzymology, 309:467-476 (1999)	
	C P	WOOD, et al., "Selective Inhibition of A β fibril formation", J. Biological Chemistry, 271(8):4086-4092 (1996)	
	C Q	ZOGHBI, HY and ORR, HT, "Polyglutamine diseases: protein cleavage and aggregation", Current Opinions in Neurobiology, 9:566-570 (1999)	
	C R	REDDY et al., "Recent advances in understanding the pathogenesis of Huntington's disease", Trends Neurosci., 22:248-255 (1999)	
	C S	CUMMINGS, CJ, and ZOGHBI, HY, "Fourteen and counting: unraveling trinucleotide repeat diseases", Human Molecular Genetics, 9(6):909-916 (2000)	
	C T	WOOD et al., "Seeding of A β fibril formation is inhibited by all three isotypes of apolipoprotein E", Biochemistry, 35:12623-12628 (1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language translation is attached.